Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? von Grimwade, David, Freeman, Sylvie D.

Volltext

Delving the depths of measurable residual disease negativity in acute myeloid leukemia von Freeman, Sylvie D

Volltext

Assessment of Minimal Residual Disease in Standard-Risk AML von Ivey, Adam, Hills, Robert K, Simpson, Michael A, Jovanovic, Jelena V, Gilkes, Amanda, Grech, Angela, Patel, Yashma, Bhudia, Neesa, Farah, Hassan, Mason, Joanne, Wall, Kerry, Akiki, Susanna, Griffiths, Michael, Solomon, Ellen, McCaughan, Frank, Linch, David C, Gale, Rosemary E, Vyas, Paresh, Freeman, Sylvie D, Russell, Nigel, Burnett, Alan K, Grimwade, David

Volltext

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations von Freeman, Sylvie D, Hills, Robert K, Virgo, Paul, Khan, Naeem, Couzens, Steve, Dillon, Richard, Gilkes, Amanda, Upton, Laura, Nielsen, Ove Juul, Cavenagh, James D, Jones, Gail, Khwaja, Asim, Cahalin, Paul, Thomas, Ian, Grimwade, David, Burnett, Alan K, Russell, Nigel H

Volltext

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia von FREEMAN, Sylvie D, VIRGO, Paul, COUZENS, Steve, GRIMWADE, David, RUSSELL, Nigel, HILLS, Robert K, BURNETT, Alan K

Volltext

Evaluating measurable residual disease in acute myeloid leukemia von Ravandi, Farhad, Walter, Roland B., Freeman, Sylvie D.

Volltext

Acute myeloid leukaemia von DiNardo, Courtney D, Erba, Harry P, Freeman, Sylvie D, Wei, Andrew H

Volltext

Transplant in older adults with AML: genomic wheat and chaff von Freeman, Sylvie D., Valk, Peter

Volltext

Reply to G. Gui et al von Craddock, Charles, Jackson, Aimee, Freeman, Sylvie D.

Volltext

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia von Khan, Naeem, Hills, Robert K, Knapper, Steve, Steadman, Lora, Qureshi, Ushna, Rector, Jerrald L, Bradbury, Charlotte, Russell, Nigel H, Vyas, Paresh, Burnett, Alan K, Grimwade, David, Hole, Paul S, Freeman, Sylvie D

Volltext

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia von Craddock, Charles, Jackson, Aimee, Loke, Justin, Siddique, Shamyla, Hodgkinson, Andrea, Mason, John, Andrew, Georgia, Nagra, Sandeep, Malladi, Ram, Peniket, Andrew, Gilleece, Maria, Salim, Rahuman, Tholouli, Eleni, Potter, Victoria, Crawley, Charles, Wheatley, Keith, Protheroe, Rachel, Vyas, Paresh, Hunter, Ann, Parker, Anne, Wilson, Keith, Pavlu, Jiri, Byrne, Jenny, Dillon, Richard, Khan, Naeem, McCarthy, Nicholas, Freeman, Sylvie D

Volltext

MRD evaluation of AML in clinical practice: are we there yet? von Freeman, Sylvie D, Hourigan, Christopher S

Volltext

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? von Grimwade, David, Freeman, Sylvie D

Volltext

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia von Milne, Paul, Wilhelm-Benartzi, Charlotte, Grunwald, Michael R., Bigley, Venetia, Dillon, Richard, Freeman, Sylvie D., Gallagher, Kathleen, Publicover, Amy, Pagan, Sarah, Marr, Helen, Jones, Gail L., Dickinson, Anne M., Grech, Angela, Burnett, Alan K., Russell, Nigel H., Levis, Mark, Knapper, Steven, Collin, Matthew

Volltext

Siglec-5 (CD170) Can Mediate Inhibitory Signaling in the Absence of Immunoreceptor Tyrosine-based Inhibitory Motif Phosphorylation von Avril, Tony, Freeman, Sylvie D., Attrill, Helen, Clarke, Rosemary G., Crocker, Paul R.

Volltext

Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis von Short, Nicholas J., Fu, Chenqi, Berry, Donald A., Walter, Roland B., Freeman, Sylvie D., Hourigan, Christopher S., Huang, Xuelin, Gonzalez, Graciela Nogueras, Hwang, Hyunsoo, Qi, Xinyue, Kantarjian, Hagop, Zhou, Shouhao, Ravandi, Farhad

Volltext

AML in the elderly—A global view von Hokland, Peter, Fernández, Isolda I., Freeman, Sylvie D., Gjertsen, Bjørn T., Jin, Jie, Murthy, Vidhya, Yanada, Masamitsu, Ganser, Arnold

Volltext

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial von Freeman, Sylvie D, Thomas, Abin, Thomas, Ian, Hills, Robert K, Vyas, Paresh, Gilkes, Amanda, Metzner, Marlen, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Rachel, Almuina, Nuria Marquez, Burns, Sarah, King, Sophie, Andrew, Georgia, Gallagher, Kathleen M E, Sellar, Rob S, Cahalin, Paul, Weber, Duruta, Dennis, Mike, Mehta, Priyanka, Knapper, Steven, Russell, Nigel H

Volltext

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML von Othman, Jad, Potter, Nicola, Mokretar, Katya, Taussig, David, Khan, Anjum, Krishnamurthy, Pramila, Latif, Anne-Louise, Cahalin, Paul, Aries, James, Amer, Mariam, Belsham, Edward, Conneally, Eibhlin, Craddock, Charles, Culligan, Dominic, Dennis, Mike, Duncan, Caroline, Freeman, Sylvie D., Furness, Caroline, Gilkes, Amanda, Gkreka, Paraskevi, Hodgson, Katherine, Ingram, Wendy, Jain, Manish, King, Andrew, Knapper, Steven, Kottaridis, Panagiotis, McMullin, Mary Frances, Mohite, Unmesh, Ngu, Loretta, O’Nions, Jenny, Patrick, Katharine, Rider, Tom, Roberts, Wing, Severinsen, Marianne Tang, Storrar, Neill, Taylor, Tom, Russell, Nigel H., Dillon, Richard

Volltext

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia von Buccisano, Francesco, Dillon, Richard, Freeman, Sylvie D, Venditti, Adriano

Volltext